Clinical trials: Sunitinib
Kidney Cancer
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01164228
- Testing
- Gemcitabine, Sunitinib
- Where
- 99 sites in United States
- Volunteers
- 87 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00482911
- Testing
- cyclophosphamide, lenalidomide, sunitinib malate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00398112
- Testing
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
- Trial name
- NCT00443534
- Testing
- SU011248
- Where
- 62 sites in United States, Canada and 5 more
- Volunteers
- 123 people
- Sponsor
- Pfizer
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Renal Cell Carcinoma
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical…
- Trial name
- NCT01502228
- Testing
- 150-Water, 62Cu-ethylglyoxal bis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Extensive-Stage Small Cell Lung Cancer
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
The goal of this study is to determine the progression-free survival rate in patients with extensive-stage small cell lung cancer who had achieved complete response, partial response, or stable disease with their previous…
- Trial name
- NCT00616109
- Testing
- sunitinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Kidney Neoplasms
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.
- Trial name
- NCT04669366
- Testing
- sunitinib, axitinib
- Where
- Sweden
- Volunteers
- 1,205 people
- Sponsor
- Pfizer
Kidney Cancer
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00849186
- Testing
- sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Multimodality Phase II Study in Prostate Cancer
This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy…
- Trial name
- NCT00734851
- Testing
- Docetaxel, Sunitinib, EBXRT
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
OPALINE : A Study Of Morbidity And Mortality At 2 Years
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease…
- Trial name
- OPALINE (NCT02264665)
- Testing
- sunitinib, everolimus, chemotherapies recommended in france
- Where
- 35 sites in France
- Volunteers
- 144 people
- Sponsor
- Pfizer
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura.
- Trial name
- NCT00392444
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01620216
- Testing
- Antitumor Drug Screening Assay, Dasatinib, Idelalisib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Urinary Tract Urothelial Carcinoma
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
A majority of patients with bladder cancer have disease confined to the inner lining of the bladder. Patients with high risk features (high grade tumors, tumors invading into a deeper superficial layer) are routinely treated with…
- Trial name
- Sutent (NCT00794950)
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Well-differentiated Pancreatic Neuroendocrine Tumor
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
- Trial name
- NCT01525550
- Testing
- sunitinib
- Where
- 26 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Pfizer
Von Hippel-Lindau Syndrome
Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
This open-label study will pilot the use of systemic sunitinib malate, a dual inhibitor of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), in five participants with Von Hippel-Lindau (VHL) to…
- Trial name
- VHL3 (NCT00673816)
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Eye Institute (NEI)